AzTrials
AzTrials

Covid19NCT04586413

Post Acute COVID-19 Quality of Life (PAC-19QoL) Tool Development and Patient Registry (PAC-19QoLReg)

An observational study of Covid19, run by Medialis Ltd. at 1 site in United Kingdom.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Coronavirus Disease 2019 (COVID-19) is a newly emerged disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The COVID-19 pandemic is having a large impact on the mental and physical health of patients, yet data on the quality of life of post-COVID-19 patients is lacking. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Covid19
How many people
100 participants
Where
1 siteUnited Kingdom
Study dates
7 Oct 2020to Oct 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Participants will have a confirmed diagnosis of COVID-19 from either a test while infected or an antibody test post infection for Phase One. Participants in Phase Two will have either confirmed test/antibody test or clinical diagnosis of COVID-19

Who may be able to join

  • The participant has had either a confirmed COVID-19 test while infected or a confirmed COVID-19 antibody test post-infection
  • The participant is aged 18 years or older
  • The participant is capable of providing informed consent
  • The participant can read, write and converse in English
  • The participant can comply with the study schedule
  • The participant has had either a confirmed COVID-19 test while infected or a confirmed COVID-19 antibody test post-infection or a clinical diagnosis of COVID-19
Show all 10Show fewer
  • The participant is aged 18 years or older
  • The participant is capable of providing informed consent
  • The participant can read, write and converse in English
  • The participant can comply with the study schedule

Who cannot join

  • The participant does not have a confirmed COVID-19 test or antibody test
  • The participant is aged under 18 years
  • The participant is not capable of giving informed consent
  • The participant is unable to read, write and converse in English
  • The participant is unable to comply with study schedule data collection
  • Phase Two
Show all 11Show fewer
  • The participant does not have a confirmed COVID-19 test or antibody test or clinical diagnosis of COVID-19
  • The participant is aged under 18 years
  • The participant is not capable of giving informed consent
  • The participant is unable to read, write and converse in English
  • The participant is unable to comply with study schedule data collection

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Omolade Femi-Ajao, PhD contact

+447502228066

research@medialis.co.uk

United Kingdom1 site, 1 recruiting
  • Medialis

    Oxford, OX16 0AH

    Ravi Jandhyala, 44(0)1744865, ravi@medialis.co.uk

    Recruiting

Other trials in United Kingdom

About this study

Coronavirus Disease 2019 (COVID-19) is a newly emerged disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The COVID-19 pandemic is having a large impact on the mental and physical health of patients, yet data on the quality of life of post-COVID-19 patients is lacking. There are currently no post-COVID-19 specific measures for quality of life, particularly none which include the views of post-COVID-19 patients themselves. This observational study will recruit participants to contribute their preferences to the creation of a post-COVID-19 specific patient-reported measure on post-COVID-19 quality of life. Participants will be split into three groups: those who were not hospitalised; those who were hospitalised but not in intensive care units; and those who were hospitalised and in intensive care units. The creation of this measure will form phase 1 of the study, with 30-60 participants (10-20 in each group above) recruited to complete online surveys to find out their preferences of areas of life to include in such a measure. This will involve 3 online surveys, 1) to ask which areas of life they feel are impacted and how; 2) to find consensus about the areas to be included; 3) to weight the relevance of these areas in relation to each other. In phase 2 recruitment will open to additional participants and all participants will be asked to complete the finalised post-COVID-19 quality of life measure once a month for 12 months, aiming for a minimum of 100 participants at this stage. All participants will also be asked to complete a demographic questionnaire to inform the analysis of the data.

Read the detailed description

This observational study will be conducted in two phases:

Phase 1 - the development of a post-COVID-19 patient reported quality of life measure Phase 2 - the longitudinal completion of the quality of life tool by post-COVID-19 patients each month for 12 months All participants will complete an online informed consent form and a demographic questionnaire at the start of their involvement with the study Phase 1 The study will recruit a minimum of 30 participants and a maximum of 60 participants, 10-20 across three groups: those who were not hospitalised; those who were hospitalised but not in intensive care units; and those who were hospitalised and in intensive care units. Investigators will take the first 10-20 participants who match in each group. If contact is received from participants but their group is already full they will be asked if they are still be happy to participate in phase 2 and an offer to contact them when that commences will be made.

Firstly, a novel method (Jandhyala Method) will be used to elicit post-COVID-19 patients' preferences for a post-COVID-19 quality of life tool. Participants will do this by completing an Awareness Round survey, this means using free-text responses to ask participants about the areas of their lives impacted by COVID-19 and those areas they see as most important to their quality of life. The research team will collate and code these free text responses then create a comprehensive list of all of those deemed important to participants who will then be sent a Consensus Round survey to ask how far they agree or disagree with the inclusion of those items in a quality of life tool. Researchers will then collate this information, group it into relevant domains and develop a weighting tool to be sent to participants to ask them to rate the relevant importance of the different areas to be included, which will be used to create weighted domain and item scores to be used in a final quality of life tool. We expect for the Awareness round surveys to be completed within a one month time period and then two weeks will be allocated for the research team to analyse and finalise the Consensus round survey; the Consensus round survey will then be open for two weeks, with prompting to participants after one week if not completed. The research team will then have a further two weeks to complete the weighting tool and participants will be given a further two weeks to complete this. At this stage the research team will have a further two weeks to finalise the Post-COVID-19 quality of life tool and then phase 2 will begin.

In summary:

  1. Awareness round online survey (hosted on Survey Monkey) - asking for areas of life which the participants feel have been impacted by COVID-19, including details and examples of those impacts
  2. The research team will collate and code these responses and generate a list of statements based on the information provided by participants
  3. Consensus round online survey (hosted on Survey Monkey) - the list of statements will be sent to participants and they will be asked to rate how far they agree or disagree with the inclusion of these areas in a post-COVID-19 quality of life tool
  4. The research team will collate this information, group it into relevant domains and develop a weighting tool
  5. Weighting tool (online Microsoft excel template) - participants will be asked to weight the individual items and domains for the finalised post-COVID-19 quality of life tool using an online excel spreadsheet template a. The research team will use this information to develop the finalised post-COVID-19 quality of life measure to be completed by participants and to develop the system to score this tool Phase 2 At this stage the recruitment will be re-opened for additional participants, including those with a clinical diagnosis regardless of test status, aiming for a minimum of 100 and a maximum of 5000 at this stage, though this will be subject to review. Recruitment will remain open for time 1 surveys for one year, with a another year following this to gain the full 12 months of data from participants, again subject to review. The finalised post-COVID-19 quality of life measure will be hosted on a secure online system (Castor EDC tm) and participants will be allocated an ID number. They will be asked to complete this measure at monthly intervals for a period of 12 months. The research team will analyse the changes over time within and between groups. Statistical methods for this will be finalised when the measure has been completed at the end of Phase 1 by our biostatistician.
Conditions
Covid19
Being tested
No intervention - quality of life measure
Keywords
Covid19, Quality of Life, Post-Covid19
Medical subject headings
COVID-19

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • No intervention - quality of life measureOther

    Participants will be part of the creation of a Post-COVID-19 quality of life measure if involved in Phase One. In Phase Two participants will complete this post-COVID-19 quality of life measure monthly for 12 months

Study groups in NCT04586413
Study groupRoleWhat they receive
Non-hospitalised post-COVID-19 patientsThis cohort will have had a confirmed positive test for COVID-19 or antibody test confirming they had COVID-19 but they were not hospitalised for this
Receives: Other: No intervention - quality of life measure
Hospitalised post-COVID-19 patientsThis cohort will have a confirmed diagnosis of COVID-19 and been hospitalised but were not in an Intensive Care Unit
Receives: Other: No intervention - quality of life measure
Intensive care post-COVID-19 patientsThis cohort will have a confirmed diagnosis of COVID-19 and been hospitalised in an Intensive Care Unit
Receives: Other: No intervention - quality of life measure

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Design of PAC19QoL Measure (Phase One)

    The design and creation of a Post-COVID-19 Quality of Life Measure

    Measured: 3 months

  2. Completion of PAC19QoL Measure monthly for 12 months (Phase Two)

    Participants in Phase Two will complete the newly designed Post-COVID-19 quality of life measure each month for 12 months

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Oct 2020
  2. Study start7 Oct 2020
  3. Primary completionOct 2028 (estimated)
  4. Study completionOct 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04586413
Sponsor's protocol ID
Med_Asst 33
Status last verified
Oct 2023
First submitted
7 Oct 2020
Last updated
23 Oct 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: No IPD

Publications

  • Jandhyala R. Design, validation and implementation of the post-acute (long) COVID-19 quality of life (PAC-19QoL) instrument. Health Qual Life Outcomes. 2021 Sep 28;19(1):229. doi: 10.1186/s12955-021-01862-1.

    PubMed 34583690

Questions about this trial

What is this clinical trial studying?

An observational study of Covid19, run by Medialis Ltd. at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 23 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Omolade Femi-Ajao, PhD (+447502228066, research@medialis.co.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Design of PAC19QoL Measure (Phase One) (time frame: 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04586413, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in